Okerson, T., Yan, P., Stonehouse, A
Our integration with LillyDirects self-pay pharmacy provider further enhances LifeMD patients experience with seamless access to branded Zepbound vials at the newly reduced self-pay price
Protocol 1: moderate weight loss (10-15% body weight) Goal: Steady, sustainable weight loss with minimal side effects Tirzepatide approach: Standard escalation to 5-7.5 mg Hold at the dose where you achieve consistent weekly loss of 0.5-1% body weight Expected timeline: 24-36 weeks to target Likely maintenance dose: 5-7.5 mg Retatrutide approach: Standard escalation to 4 mg 4 mg delivered 12.9% weight loss at 24 weeks in trials Hold at 4 mg if achieving target rate Expected timeline: 20-30 weeks to target For moderate goals, both compounds work well at their lower dose ranges
Curious if you can comment on when the 24.4 AF topics will be loaded into DSIP
A number of the researchers had financial entanglements with the drug manufacturer
20% of these adults are obese, or 11m people